drugset
drugset / Trial / NCT06516510

A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer

NCT06516510 ↗

Phase 0 Terminated 17 enrolled Blue Earth Therapeutics Ltd Medpace, Inc. · collab
RandomizedCrossoverSingle-blindOther

Summary

A randomised, multi-centre, intra-patient imaging and dosimetry crossover study of lutetium (177Lu) rhPSMA 10.1 and lutetium (177Lu) vipivotide tetraxetan (Pluvicto®) in patients with non-curative metastatic prostate cancer

Timeline

Start
2024-10-31
Primary completion
2025-08-15
Completion
2025-08-15

Drugs

EvaluationDrugModalityDoseRoute
Subject 177Lu-PSMA-617 Other / unclassified — —
Subject LUTETIUM TEZUVOTIDEXETAN Other / unclassified — —

Indications

metastatic prostate carcinoma